Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2002; 87(06): 928-929
DOI: 10.1055/s-0037-1613113
DOI: 10.1055/s-0037-1613113
Commentary
Blood Clotting Activation, Angiogenesis and Tumor Metastasis: Any Role for TFPI?
Authors
Further Information
Publication History
Received
02 April 2002
Accepted
02 April 2002
Publication Date:
08 December 2017 (online)
-
References
- 1 Rickles FR, Levine MN. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998; 28 (Suppl. 03) 43-9.
- 2 Falanga A, Donati MB. Pathogenesis of thrombosis in patients with malignancy. Int J Hematol 2001; 73: 137-44.
- 3 Donati MB, Semeraro N. Cancer cell procoagulants and their pharmacological modulation. Haemostasis 1984; 14: 422-9.
- 4 Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-6.
- 5 Napoleone E, Di Santo A, Lorenzet R. Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood 1997; 89: 541-9.
- 6 Lorenzet R, Napoleone E, Celi A, Pellegrini G, Di Santo AM. Cell-cell interaction and tissue factor expression. Blood Coagul Fibrinol 1998; 09 (Suppl. 01) S49-S59.
- 7 Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24: 5558-67.
- 8 Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood 1988; 71: 870-5.
- 9 Donati MB, Gambacorti-Passerini C, Casali B, Falanga A, Vannotti P, Fossati G, Semeraro N, Gordon SG. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 1986; 46 (12 Pt 1) 6471-4.
- 10 Lorenzet R, Peri G, Locati D, Allavena P, Colucci M, Semeraro N, Mantovani A, Donati MB. Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. Blood 1983; 62: 271-3.
- 11 Rambaldi A, Alessio G, Casali B, Gambacorti-Passerini C, Donati MB, Mantovani A, Semeraro N. Induction of monocyte-macrophage procoagulant activity by transformed cell lines. J Immunol 1986; 136 (10) 3848-55.
- 12 Falanga A, Marchetti M, Giovanelli S, Barbui T. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4). Blood 1996; 87 (02) 613-7.
- 13 Colucci M, Giavazzi R, Alessandri G, Semeraro N, Mantovani A, Donati MB. Procoagulant activity of sarcoma sublines with different metastatic potential. Blood 1981; 57: 733-5.
- 14 Bromberg ME, Konisberg WH, Madison JF, Pawashe A, Goren A. Tissue factor promotes melanoma metastases by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 8205-9.
- 15 Contrino J, Hair GA, Schmeizl MA, Rickles FR, Kreutzer DL. In situ characterization of antigenic and functional tissue factor expression in human tumors utilizing monoclonal antibodies and recombinant factor VIIa as probes. Am J Pathol 1994; 145 (06) 1315-22.
- 16 Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992; 89: 11832-6.
- 17 Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998; 101: 1372-8.
- 18 Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Med 1996; 02: 209-15.
- 19 Colucci M, Delaini F, de Bellis GVitti, Locati D, Poggi A, Semeraro N, Donati MB. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. Biochem Pharmacol 1983; 32 (11) 1689-91.
- 20 Ornstein DL, Zacharski LR. Treatment of cancer with anticoagulants: rationale in the treatment of melanoma. Int J Hematol 2001; 73 (02) 157-61.
- 21 Broze Jr GJ. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinol 1995; (Suppl. 01) S7-S13.
- 22 Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-72.
- 23 de Jonge E, Dekkers PEP, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, van Deventer SJH, van der Poll T. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-9.
- 24 Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28 (Suppl.): S31-S33.
- 25 Donati MB. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74: 278-81.
- 26 Fischer EG, Riewald M, Huang HY, Miyagi Y, Kubota Y, Mueller BM, Ruf W. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest 1999; 104 (09) 1213-21.